Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction

World Journal of Gastroenterology

Volumn 18, Issue 21, 2012, Pages 2735-2738

  Nishizawa, Toshihiro ^a   Suzuki, Hidekazu ^b   Maekawa, Takama ^a   Harada, Naohiko ^c   Toyokawa, Tatsuya ^d   Kuwai, Toshio ^e   Ohara, Masanori ^e   Suzuki, Takahiro ^f   Kawanishi, Masahiro ^g   Noguchi, Kenji ^h   Yoshio, Toshiyuki ^e   Katsushima, Shinji ^a   Tsuruta, Hideo ⁱ   Masuda, Eiji ^j   Tanaka, Munehiro ^k   Katayama, Shunsuke ^l   Kawamura, Norio ^m   Nishizawa, Yuko ⁿ   Hibi, Toshifumi ^b   Takahashi, Masahiko ^a  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f Japan   (Japan)

^g National Hospital Organization Higashihiroshima Medical Center   (Japan)

^h SENDAI CITY MEDICAL CENTER   (Japan)

ⁱ Ureshino Medical Center   (Japan)

^j MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^k FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^l National Hospital Organisation Yonago Medical Center   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

ⁿ NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

more..

Author keywords

Amoxicillin; Dual therapy; Eradication; Helicobacter pylori; Urea breath test

Indexed keywords

AMOXICILLIN; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HELICOBACTER PYLORI; HUMAN; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PREDICTION; PROSPECTIVE STUDY; STOMATITIS; UREA BREATH TEST;

EID: 84863093027     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i21.2735     Document Type: Article

References (26)

1. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after end oscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-397
2. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother 2009; 53: 1720-1721
3. Nishizawa T, Suzuki H, Hibi T. Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication. J Clin Biochem Nutr 2009; 44: 119-124
4. Nishizawa T, Suzuki H, Masaoka T, Minegishi Y, Iwasahi E, Hibi T. Helicobacter pylori eradication restored sonic hedgehog expression in the stomach. Hepatogastroenterology 2007; 54: 697-700
5. Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 2006; 41: 513-523
6. Suzuki H, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol 2011; 26 Suppl 3: 42-45
7. Suzuki M, Suzuki H, Minegishi Y, Ito K, Nishizawa T, Hibi T: H pylori-Eradication Therapy Increases RUNX3 Expression in the Glandular Epithelial Cells in Enlarged-Fold Gastritis. J Clin Biochem Nutr 2010; 46: 259-264
8. Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol 2010; 5: 639-648
9. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, Matsuzaki J, Hibi T. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol 2010; 25 Suppl 1: S75-S79
10. Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr 2010; 47: 53-58
11. Nishizawa T, Suzuki H, Masaoka T, Iwasaki E, Hibi T. A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori. Digestion 2007; 76: 215-220
12. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003; 50: 2274-2278
13. Nishizawa T, Suzuki H, Nakagawa I, Iwasaki E, Masaoka T, Hibi T. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol 2008; 23 Suppl 2: S167-S170
14. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-1937
15. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76: 290-301
16. Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Ikuma M, Shirai N. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology 2010; 57: 1314-1319
17. Logan RP, Polson RJ, Misiewicz JJ, Rao G, Karim NQ, Newell D, Johnson P, Wadsworth J, Walker MM, Baron JH. Simplified single sample 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology. Gut 1991; 32: 1461-1464
18. Kobayashi D, Eishi Y, Ohkusa T, Ishige T, Minami J, Yamada T, Takizawa T, Koike M. Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 2002; 51: 305-311
19. Nishizawa T, Suzuki H, Kurabayashi K, Masaoka T, Muraoka H, Mori M, Iwasaki E, Kobayashi I, Hibi T. Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother 2006; 50: 1538-1540
20. Nishizawa T, Suzuki H, Umezawa A, Muraoka H, Iwasaki E, Masaoka T, Kobayashi I, Hibi T. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J Clin Microbiol 2007; 45: 303-305
21. Suzuki S, Suzuki H, Nishizawa T, Kaneko F, Ootani S, Muraoka H, Saito Y, Kobayashi I, Hibi T. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori. Digestion 2009; 79: 1-4
22. Gisbert JP, Castro-Fernández M, Bermejo F, Pérez-Aisa A, Ducons J, Fernández-Bermejo M, Bory F, Cosme A, Benito LM, López-Rivas L, Lamas E, Pabón M, Olivares D. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101: 243-247
23. González Carro P, Pérez Roldán F, De Pedro Esteban A, Legaz Huidobro ML, Soto Fernández S, Roncero Garcia Escribano O, Esteban López-Jamar JM, Pedraza Martin C, Ruíz Carrillo F. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol 2007; 22: 60-63
24. Nishizawa T, Suzuki H, Matsuzaki J, Muraoka H, Tsugawa H, Hirata K, Hibi T. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob Agents Chemother 2011; 55: 5374-5375
25. Nishizawa T, Suzuki H, Tsugawa H, Muraoka H, Matsuzaki J, Hirata K, Ikeda F, Takahashi M, Hibi T. Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication. Antimicrob Agents Chemother 2011; 55: 3012-3014
26. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14: 5385-5402